5′-triphosphate-siRNA: Turning gene silencing and Rig-I activation against melanoma

Nature Medicine

Volumn 14, Issue 11, 2008, Pages 1256-1263

  Poeck, Hendrik ^a,b,c   Besch, Robert ^b   Maihoefer, Cornelius ^b,c   Renn, Marcel ^d   Tormo, Damia ^d   Morskaya, Svetlana Shulga ^e   Kirschnek, Susanne ^f   Gaffal, Evelyn ^d   Landsberg, Jennifer ^d   Hellmuth, Johannes ^a   Schmidt, Andreas ^b   Anz, David ^b   Bscheider, Michael ^b,c   Schwerd, Tobias ^b   Berking, Carola ^b   Bourquin, Carole ^b   Kalinke, Ulrich ^g   Kremmer, Elisabeth ^h   Kato, Hiroki ⁱ   Akira, Shizuo ⁱ   Meyers, Rachel ^e   Häcker, Georg ^f   Neuenhahn, Michael ^f   Busch, Dirk ^f   Ruland, Jürgen ^c   Rothenfusser, Simon ^b   Prinz, Marco ^j   Hornung, Veit ^a   Endres, Stefan ^b   Tüting, Thomas ^d   Hartmann, Gunther ^a   more..

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e ALNYLAM PHARMACEUTICALS   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g PAUL EHRLICH INSTITUT   (Germany)

^h INSTITUTE OF EPIDEMIOLOGY   (Germany)

ⁱ OSAKA UNIVERSITY   (Japan)

^j UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MESSENGER RNA; PROTEIN BCL 2; RETINOIC ACID INDUCIBLE PROTEIN I; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, MOUSE; DDX58 PROTEIN, HUMAN; DDX58 PROTEIN, MOUSE; DEAD BOX PROTEIN; ONCOPROTEIN; PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; FEMALE; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LUNG METASTASIS; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR CELL; ANIMAL; CELL TRANSPLANTATION; DISEASE MODEL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSPLANTATION; DEAD-BOX RNA HELICASES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNITY, INNATE; MELANOMA; MICE; PHOSPHATES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING;

EID: 55549114663     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1887     Document Type: Article

References (31)

1. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Bui, J.D. & Schreiber, R.D. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol. 19, 203-208 (2007).
3. Rubin, B.P., Heinrich, M.C. & Corless, C.L. Gastrointestinal stromal tumour. Lancet 369, 1731-1741 (2007).
4. Curiel, T.J. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117, 1167-1174 (2007).
5. Uno, T. et al. Eradication of established tumors in mice by a combination antibodybased therapy. Nat. Med. 12, 693-698 (2006).
6. Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007).
7. Schlee, M., Hornung, V. & Hartmann, G. siRNA and isRNA: two edges of one sword. Mol. Ther. 14, 463-470 (2006).
8. Pei, Y. & Tuschl, T. On the art of identifying effective and specific siRNAs. Nat. Methods 3, 670-676 (2006).
9. de Fougerolles, A., Vornlocher, H.P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443-453 (2007).
10. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in doublestranded RNA-induced innate antiviral responses. Nat. Immunol. 5, 730-737 (2004).
11. Hornung, V. et al. 5′-triphosphate RNA is the ligand for RIG-I. Science 314, 994-997 (2006).
12. Pichlmair, A. et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314, 997-1001 (2006).
13. Yoneyama, M. & Fujita, T. Function of RIG-I-like receptors in antiviral innate immunity. J. Biol. Chem. 282, 15315-15318 (2007).
14. Kim, D.H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22, 321-325 (2004).
15. Miller, A.J. & Mihm, M.C. Jr. Melanoma. N. Engl. J. Med. 355, 51-65 (2006).
16. Danial, N.N. & Korsmeyer, S.J. Cell death: critical control points. Cell 116, 205-219 (2004).
17. McGill, G.G. et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718 (2002).
18. Hornung, V. et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270 (2005).
19. Judge, A.D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462 (2005).
20. Kawai, T. & Akira, S. Innate immune recognition of viral infection. Nat. Immunol. 7, 131-137 (2006).
21. Kato, H. et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19-28 (2005).
22. Melchjorsen, J. et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J. Virol. 79, 12944-12951 (2005).
23. Kawai, T. et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981-988 (2005).
24. Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005).
25. Tormo, D. et al. Therapeutic efficacy of antigen-specific vaccination and Toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66, 5427-5435 (2006).
26. Stetson, D.B. & Medzhitov, R. Antiviral defense: interferons and beyond. J. Exp. Med. 203, 1837-1841 (2006).
27. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531 (2004).
28. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
29. Muller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921 (1994).
30. Kamphuis, E., Junt, T., Waibler, Z., Forster, R. & Kalinke, U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108, 3253-3261 (2006).
31. low targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19, 561-569 (2003).